A recent useful definition of screening is 'medical investigation which does not arise from a patient's request for advice for specific complaints' (Nuffield Provincial Hospitals Trust 1968). In this screening differs from the usual form of clinical diagnosis in that the doctor is offering a benefit either to the general population or to some particular group, in contrast to patients with symptoms. For this reason, among others, screening testsEneed to be especially justified to ensure that benefits outweigh drawbacks.
In clinical pathology, particularly biochemistry, the workload of the laboratory has been roughly doubling every five years. Automation is coming to the help of the pathologist in a number of ways, but as a screening tool its effect needs close examination. 'Patient profiling' is just one example of screening, as applied to patients attending hospital.
In the United Kingdom we have, as a rule, taken a cautious view of screening and have tried to ensure that proper validation is carried out before adopting particular techniques. Important points in the evaluation of screening are:
(1) The condition sought should be important to the public health. A rough estimate of importance is given by the product: rating of severity x prevalence. For example, untreated phenylketonuria is an extremely severe condition but its prevalence is lowof the order of 1 in 10,000 births; minor degrees of iron deficiency anmmia are not serious, but it is a very common condition.
(2) There should be a reasonable balance between the cost of screening, including its consequences in follow up and treatment, and the effectiveness of its results. Screening for pulmonary tuberculosis by microscopy of the sputum is, for instance, more cost-effective than mass radiography, because it is cheaper, more specific, and leads to equally or almost equally effective treatment with current drugs and streptomycin.
(3) The natural history of the condition screened for needs to be well enough understood to justify screening. For example, it was thought that the natural history of cervical cancer was sufficiently well understood, in particular the relationship between the so-called pre-invasive condition of carcinoma-in-situ and invasive cancer. Screening by cervical cytology was accordingly introduced in most economically advanced countries, but experience so far has not succeeded in fully establishing this supposed relationship and further information is needed. (4) From knowledge of the natural history, information on the validity of screening tests and on the effectiveness of early treatment can be acquired. The relevance of screening variables such as blood sugar in diabetes or intraocular tension in chronic simple glaucoma as valid early indices of disease can be determined experimentally, and the reproducibility and accuracy of the actual tests used can be measured. For instance, it has been shown both that intraocular pressure as measured bytonometryis ofpoorvalidity in screening forchronic glaucoma, andthat measurement of the pressure using the Schiotz tonometer has poor reproducibility. The effectiveness of treatment at a preclinical stage of disease can best be demonstrated by means of randomized controlled trials. Recent work by Freis and his colleagues for example (United States Veterans' Administration 1970) has demonstrated the value of treating moderate symptomless arterial hypertension in men by these means.
(5) A further point in establishing the validity of screening is the demonstration of ability to reach the population at risk with the proffered tests. Thus it is quite possible that cervical cytology is a valid screening technique, but that the expected results have so far not been established because women at greatest risk of cancer of the cervix are the least likely to accept the screening invitation. In a number of studies it has been demonstrated that older women and those least socially privileged, two factors associated with enhanced risk of the disease, are proportionately poorly represented among all women screened. New approaches are needed to reach women at high risk, one of which is the taking of cervical smears by nurses visiting in their own homes women known to belong to a high risk group.
Many screening variables are continuously distributed in a skewed normal distribution pattern with no sign of a demarcation between 'normal' and 'abnormal' levels. A frequent practice, but one to which there are objections, is to take as within 'normal' the area of the distribution lying within i 2 standard deviations from the mean value for the population sample used, that is about 95% of the total distribution. In fact the term 'normal' is misleading, suggesting as it does a fixed range, whereas in reality no more can be done than define a probability. As Murphy & Abbey (1967) have pointed out in their paper 'The normal rangea common misuse', what is needed in defining normality is a knowledge of the range in disease, i.e. the distribution of values in what they term 'the population of interest'. For example, as they point out, a much lower and narrower range of leukocytosis is of interest in diagnosing acute appendicitis than in primary carcinoma of the liver. Also the level set for 'abnormal' needs to be much more sensitive in appendicitis because of the much greater medical 'penalty' if acute appendicitis is missed compared with liver carcinoma. Elveback et al. (1970) have also attacked the principle of plus or minus 2 standard deviations from the mean as a definition of 'normal' on two principal grounds: that in fact most biochemical values are not normally distributed but show important departures from a true gaussian distribution (this can to some extent be allowed for by transformation into a log-normal distribution), and that the population sample providing the basic frequency distribution usually consists of patients attending hospital, instead of a probability sample of the general population. Elveback and her co-workers claim that important findings may thus be missed. For example, the serum calcium in a patient with a parathyroid tumour could be classified as 'normal' when it should have been regarded as indicating the need for further investigation.
We are at present at a stage of experimentinig with the possibilities of collecting large amounts of laboratory information through automation. The present need seems to be for pathologists and clinicians to scrutinize together the tests that can be provided and determine which, under what conditions, provide the highest yield of relevant information. It is important to look closely at what we do not need to do, so as to be free to concentrate on what can usefully be found by screening.
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The Cost-effectiveness ofScreening Health services are under pressure from public demand and from developing technology. There is also pressure on costs, because productivity tends to rise more slowly in services than in manufacturing industry. One way of combating this tendency is by industrializing health care as far as possible. Screening can claim all the classic advantages of the division of labour: it enables technical specialists to be substituted for professional generalists, it uses continuous or batch processes, and it makes practicable the development and use ofmechanical aids.
Economists divide resource allocation problems into the problems of priorities, or costbenefit; techniques, or cost-effectiveness; and distributionwho gets what health care.
Screening involves questions of cost-benefit as well as cost-effectiveness. Funds are budgeted by activities, not by diseases. If introducing screening for a disease reduces the costs of conventional treatment this is likely to be a medical but not a budgetary consequence.
At a physical level, screening characteristically uses a quite different mix of resources from nonscreening methods. This is one of the arguments for screeningthat, for instance, it saves doctors' time.
